Education
About Us
Working with TipRanks
Follow Us
VolitionRX Ltd. (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.45
$0.01(1.52%)
At close: 4:00 PM EST
$0.45
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.40 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)675.36K
Market Cap
$52.90M
Enterprise Value$85.42M
Total Cash (Recent Filing)$2.26M
Total Debt (Recent Filing)$10.94M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 13, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding119,145,424
10 Day Avg. Volume1,357,047
30 Day Avg. Volume675,357
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue64.75
Enterprise Value/Gross Profit64.75
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$2.50Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Licensing AgreementsThe agreement with Werfen aligns with Volition's strategy to out-license its proprietary tests to large international companies, potentially boosting its revenue.
Partnerships And CollaborationsVolitionRx has entered an agreement with Hologic Diagenode for the co-marketing of Volition’s Nu.Q Discover service, aiming to expand its customer base.
Revenue GrowthPotential upfront and milestone payments, as well as future recurring royalties from agreements, are expected to drive Volition’s topline growth.
Bears Say
Capital NeedsThe company may need to raise additional capital in the near term if sufficient cash is not received from the upcoming licensing deal.
Financial RisksRisks include failure in clinical development of diagnostic products, failure to secure license agreements, failure to achieve market traction, dilution risk, and going concern risk and delisting risk.
VolitionRX News
VNRX FAQ
What was VolitionRX Ltd.’s price range in the past 12 months?
VolitionRX Ltd. lowest stock price was $0.40 and its highest was $0.94 in the past 12 months.
What is VolitionRX Ltd.’s market cap?
VolitionRX Ltd.’s market cap is $52.90M.
When is VolitionRX Ltd.’s upcoming earnings report date?
VolitionRX Ltd.’s upcoming earnings report date is Nov 13, 2025 which is in 17 days.
How were VolitionRX Ltd.’s earnings last quarter?
VolitionRX Ltd. released its earnings results on Aug 14, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.006.
Is VolitionRX Ltd. overvalued?
According to Wall Street analysts VolitionRX Ltd.’s price is currently Undervalued.
Does VolitionRX Ltd. pay dividends?
VolitionRX Ltd. does not currently pay dividends.
What is VolitionRX Ltd.’s EPS estimate?
VolitionRX Ltd.’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX Ltd. have?
VolitionRX Ltd. has 119,145,424 shares outstanding.
What happened to VolitionRX Ltd.’s price movement after its last earnings report?
VolitionRX Ltd. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went up 7.812%.
Which hedge fund is a major shareholder of VolitionRX Ltd.?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (455.56% Upside)
$2.50 (455.56% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $239.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.39%
Trailing 12-Months
Company Description
VolitionRX Ltd.
VolitionRx Limited (VNRX) is a biotechnology company focused on developing blood-based diagnostic tests for cancer detection and monitoring. The company operates primarily in the healthcare sector, utilizing its proprietary Nucleosomics™ technology to identify cancer-related biomarkers in the blood. VolitionRx aims to provide accurate, easy-to-use, and cost-effective diagnostic solutions that can improve patient outcomes through early detection and monitoring of cancer.
VNRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in cost reduction, revenue increase, and new product sales, alongside promising clinical study results. There was also strong progress in licensing and partnerships. However, concerns about uncertain revenue projections and decreasing cash reserves were noted.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(455.56% Upside)
Technical Analysis
Ownership Overview
11.87% Insiders
2.11% Mutual Funds
0.22% Other Institutional Investors
84.86% Public Companies and
Individual Investors